Sam Santhosh's guest appearances

Sam Santhosh

The Entrepreneur Way

Middle Market Thought Leader | Priorities for Growth

Tony Drockton

Mike Scher

Martin Rawls-Meehan

Julie Strong

Matthew Bertulli

Sanjay Govil

Brian Rowe

Norm Laviolette

Derek Lewis

Whitney Vosburgh

Jennifer James

David Walsh

Benjamin K

Nate Regier

Kevin Stone

OwlTail

Fifteen years ago, when the National Human Genome Research Institute (NHGRI) announced the successful completion of the Human Genome Project, Sam Santhosh decided that it was time to study up and find all of what was required to compete inside the world of DNA sequencing. The way that Santhosh saw it, sequencing was really about data, a world he felt he understood well and one that he was confident would yield future business opportunities. Still, the unique opportunity that would give rise to MedGenome would first escape Santhosh’s lines of sight. The opportunity: India’s historic caste structure is responsible for creating an unusual human patchwork where the population is divided into distinct groups with striking genetic differences. In the genomic world, India’s unusual population patchwork provides a yet unmatched genetic pool to test and accelerate new medical therapies—while providing insights for drug development and precision medicine. Join us when Sam explains how the opportunity came more fully into view and how building a research capability in India became the first stage in pursuing a bigger data vision.

Fifteen years ago, when the National Human Genome Research Institute (NHGRI) announced the successful completion of the Human Genome Project, Sam Santhosh decided that it was time to study up and find all of what was required to compete inside the world of DNA sequencing. The way that Santhosh saw it, sequencing was really about data, a world he felt he understood well and one that he was confident would yield future business opportunities. Still, the unique opportunity that would give rise to MedGenome would first escape Santhosh’s lines of sight. The opportunity: India’s historic caste structure is responsible for creating an unusual human patchwork where the population is divided into distinct groups with striking genetic differences. In the genomic world, India’s unusual population patchwork provides a yet unmatched genetic pool to test and accelerate new medical therapies—while providing insights for drug development and precision medicine. Join us when Sam explains how the opportunity came more fully into view and how building a research capability in India became the first stage in pursuing a bigger data vision.

204:  A One of a Kind Advantage | Sam Santhosh, CEO, MedGenome 

Sam Santhosh is an entrepreneur with more than 25 years of experience in initiating and running successful businesses. Sam is an investor and mentor for many companies and is currently an advisor to Impelsys Inc New York, ePay Healthcare, San Francisco, and a board member at SciGenom Labs, Cochin, Emerge Ventures, Singapore and the Centre for Commercialization of Antibodies (CCAB), Toronto. Prior to this, Sam was the CEO and Managing Director of California Software Limited (Calsoft) from 1992-2012. He founded Calsoft in 1992 and under his vision, Calsoft grew rapidly from a niche player in the Silicon Valley to a global player with 1,200 employees and presence in eight countries. “Be very clear about your exit plan and make sure you don’t get diluted too fast. My last rule of thumb that I tried to tell entrepreneurs and business men that you should hold on to at least 50% of your equity for the first 5 years, you and your core team, that will allow you to make sure you have control of the company and you don’t end up having too little at the end of the day”…[Listen for More] Click Here for Show Notes To Listen or to Get the Show Notes go to http://wp.me/p6Tf4b-5re

<a href="http://wp.me/p6Tf4b-5re" rel="nofollow" target="_blank">Sam Santhosh</a> is an entrepreneur with more than 25 years of experience in initiating and running successful businesses. Sam is an investor and mentor for many companies and is currently an advisor to Impelsys Inc New York, ePay Healthcare, San Francisco, and a board member at SciGenom Labs, Cochin, Emerge Ventures, Singapore and the Centre for Commercialization of Antibodies (CCAB), Toronto. Prior to this, Sam was the CEO and Managing Director of California Software Limited (Calsoft) from 1992-2012. He founded Calsoft in 1992 and under his vision, Calsoft grew rapidly from a niche player in the Silicon Valley to a global player with 1,200 employees and presence in eight countries. “Be very clear about your exit plan and make sure you don’t get diluted too fast. My last rule of thumb that I tried to tell entrepreneurs and business men that you should hold on to at least 50% of your equity for the first 5 years, you and your core team, that will allow you to make sure you have control of the company and you don’t end up having too little at the end of the day”…[Listen for More] <a href="http://wp.me/p6Tf4b-5re" rel="nofollow" target="_blank">Click Here for Show Notes</a> To Listen or to Get the Show Notes go to <a href="http://wp.me/p6Tf4b-5re" rel="nofollow" target="_blank">http://wp.me/p6Tf4b-5re</a>

763: There Is Not Much of an Opportunity for You to Rest on What You Know with Sam Santhosh Founder and Owner of MedGenome Labs Ltd